CERo Therapeutics regains Nasdaq bid price compliance; delisting hearing canceled

CERO THERAPEUTICS HOLDINGS, INC.

On July 7, 2025, Nasdaq determined CERo regained compliance with the $1.00 minimum bid price rule.
Company had received a deficiency notice on June 11, 2025, for 30 consecutive days of sub-$1.00 closing bid.
CERo timely appealed the delisting determination and requested a hearing, which stayed the suspension.
Nasdaq canceled the scheduled hearing because compliance was restored; common stock continues on Nasdaq Capital Market.
Tickers CERO (common) and CEROW (warrants) remain listed on the Nasdaq Capital Market.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.